Epigenomics Inc

Website Links

Description

Molecular diagnostics is a multi-billion euro market opportunity with the greatest future growth expected to be driven by oncology tests. We follow an integrated strategy and business model of partnering our blood-based screening tests and development of our own tissue-based molecular diagnostic products in our SBU Diagnostics. Clinical Solutions offers integrated biomarker solutions, and we aim at establishing a gold standard in DNA methylation via out-licensing.Own product development & commercialization. The primary focus of product development will be two tissue-based tests directed at prostate and breast cancer molecular classification, leveraging DNA methylation markers and assays that already have significant clinical validation.Our strategy for own product development builds on creating the organizational infrastructure and developing the required expertise inhouse. Its based on having full control over the entire process of clinical validation and clinical development, as well as regulatory approval, and positioning of the products. At the same time, we expect to work closely with OEM (original equipment manufacturing) partners for key components of our overall product. Both the patient sample processing kits as well as the IVD testing devices will be manufactured for Epigenomics.

Company contacts

Products & services

Similar companies nearby